OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial - Concepedia

Concepedia

Publication | Closed Access

OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

20

Citations

0

References

2017

Year

Myung‐Ju Ahn, D. Ross Camidge, Marcello Tiseo, Karen L. Reckamp, Karin Holmskov Hansen, S. Kim, Rudolf M. Huber, Howard West, Harry J.M. Groen, Maximilian J. Hochmair,

Journal of Thoracic Oncology

OncologyMetronomic TherapyPharmacologyCrizotinib-refractory Alk+ NsclcPharmacotherapyMedicineRandomized Phase 2

No additional data available for this publication yet. Check back later!